Spravato ® (esketamine) – New indication
August 3, 2020 - Janssen announced the FDA approval of Spravato (esketamine), in conjunction with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.
Download PDF
